Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06784336

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Led by University of Michigan Rogel Cancer Center · Updated on 2025-11-28

50

Participants Needed

1

Research Sites

206 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.

CONDITIONS

Official Title

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with hematologic disorders undergoing allo-HCT from fully HLA-matched unrelated or related donors after full-intensity conditioning regimen
  • Age 18 years or older
  • Karnofsky performance status greater than 70%
  • Patients must be able to swallow capsules or tablets
  • Ability to understand and willingness to sign informed consent
  • Availability of a full-HLA matched donor medically eligible to donate cells according to National Marrow Donor Program criteria
Not Eligible

You will not qualify if you...

  • Active inflammatory bowel disease requiring treatment
  • History of gastric bypass surgery
  • Active Clostridium difficile infection at enrollment
  • Active iron deficiency anemia requiring treatment
  • Iron overload receiving active deferasirox treatment
  • Known hypersensitivity to deferasirox or components of Jadenu or Exjade
  • Currently enrolled or in follow-up on any other GVHD prevention trial
  • Any physical or psychological condition posing unacceptable risk or concern for protocol compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, United States, 48187

Actively Recruiting

Loading map...

Research Team

M

Mary Riwes

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here